RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Bone Cancer
  Breast Cancer
  Cervical Cancer
  Gastric Cancer
  Liver Cancer
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Testicular Cancer
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Gastric Cancer Channel

subscribe to Gastric Cancer newsletter
Latest Research : Cancer : Gastric Cancer

   EMAIL   |   PRINT
Long term benefits of Imatinib in advanced gastrointestinal stromal tumors (GIST) confirmed

Jun 5, 2006 - 4:37:00 PM , Reviewed by: Priya Saxena
"This study shows that the response to Gleevec among GIST patients is durable. Molecularly targeted therapy helps extend their lives."

[RxPG] People with advanced gastrointestinal stromal tumors (GIST) who take Imatinib for prolonged periods continue to benefit from the drug, according to a five-year study by Oregon Health & Science University Cancer Institute researchers.

It represents the long-term analysis of a randomized clinical trial begun in 2000. More than half of study participants saw their GIST go into remission on Gleevec. Those promising early results prompted the U.S. Food and Drug Administration to approve Gleevec as a treatment for GIST on Feb. 1, 2002.

The long-term analysis, completed in 2005, continues to demonstrate promising results. Eighty-four percent of the 147 GIST study participants on Gleevec showed clinical improvement during the study period, meaning that their disease stabilized or went into remission. Two of those experienced complete remission. However, some subjects developed resistance to the drug and some experienced a relapse of their cancer.

It typically took 13 weeks before a study participant responded to the drug, and the typical positive response lasted 118 weeks (2.3 years).

"This study shows that the response to Gleevec among GIST patients is durable," Blanke said. "Molecularly targeted therapy helps extend their lives."

The long-term study of GIST is especially significant because GIST is a cancer that has been considered untreatable and incurable, with life expectancy of about a year. People in the Gleevec study survived a median of 4.8 years.

Gleevec is a signal transduction inhibitor that interferes with the enzymes that trigger the spread of tumor cells. It acts on GIST by blocking the growth signal of genetic mutations called c-kit and PDGFRA. Subjects with either of these mutations were more likely to respond to Gleevec than those without the mutations.

Most of the persons in the study for whom Gleevec did not work developed resistance to the drug. Among those who developed resistance, the median time to do so was 84 weeks (1.6 years).

Gleevec was initially developed at the OHSU Cancer Institute by Brian Druker, M.D., in collaboration with scientists at Novartis, as a treatment for patients with chronic myelogenous leukemia. In addition to GIST, it is also being studied as a potential therapy for certain types of blood and skin cancers.

Publication: The study was presented at the 2006 annual meeting of the American Society of Clinical Oncology on Sunday, June 4, in Atlanta, Ga.
On the web: www.ohsu.edu 

Advertise in this space for $10 per month. Contact us today.

Related Gastric Cancer News
Genetic mutations identified for type of gastric cancer
Less than one third gastric cancer patients actually have adequate lymph node assessments
Long term benefits of Imatinib in advanced gastrointestinal stromal tumors (GIST) confirmed
New discoveries to tackle stomach cancer
Stomach cancer formation can be supressed by by lowering Stat3 hyperactivity

Subscribe to Gastric Cancer Newsletter

Enter your email address:

 Additional information about the news article

The study was led by Charles Blanke, M.D., leader of the OHSU Cancer Institute Solid Tumors Program, with colleagues at OHSU, Dana-Farber Cancer Institute, the Fox Chase Cancer Center, and the University of Helsinki.

This study was funded by Novartis.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)